Follicular Lymphoma (FL)

Follicular lymphoma (FL) accounts for the vast majority of indolent non-Hodgkin's lymphomas (NHLs).1

  • In 2013, there were an estimated 569,536 people living with NHL in the United States2
  • FL is the second most common subtype of NHL, representing about 20% of NHLs2,3
  • The median age at diagnosis of FL patients in the United States is 60 years3

Understanding the disease biology, diagnostic and prognostic indicators, and treatment options has improved the outlook for FL patients.4

  • Although the disease is not curable, FL typically can be managed over time


  1. Friedberg JW. Treatment of follicular non-Hodgkin's lymphoma: the old and the new. Semin Hematol. 2008;45(3 suppl 2):S2-S6. doi:10:1053/j.seminhematol.2008.07.003.
  2. National Cancer Institute. Survelliance, Epidemiology, and End Results Program. Estimated United States Cancer Prevalence Counts on January 1, 2013. Available at: Accessed January 25, 2017.
  3. Freedman AS, Friedberg JW, Mauch PM, Dalla-Favera R, Harris NL. Follicular lymphoma. In: Armitage JO, Mauch PM, Harris NL, Coiffier B, Dalla-Favera R, eds. Non-Hodgkin Lymphomas. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:266-283.
  4. Hagenbeek A. Maintenance or eradication of residual disease in indolent lymphoma: where do we stand? J Clin Oncol. 2009;27:1540-1542.